1. Home
  2. PRE vs ADAG Comparison

PRE vs ADAG Comparison

Compare PRE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$15.47

Market Cap

295.3M

Sector

Industrials

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.58

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
ADAG
Founded
2014
2011
Country
Hong Kong
China
Employees
285
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.3M
254.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PRE
ADAG
Price
$15.47
$3.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$30.50
$8.25
AVG Volume (30 Days)
176.0K
151.8K
Earning Date
06-11-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$108.69
N/A
Revenue Next Year
$58.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$1.44
52 Week High
$23.63
$4.75

Technical Indicators

Market Signals
Indicator
PRE
ADAG
Relative Strength Index (RSI) 38.53 45.25
Support Level $14.67 $3.40
Resistance Level $17.76 $3.99
Average True Range (ATR) 1.28 0.28
MACD 0.03 -0.01
Stochastic Oscillator 12.64 54.48

Price Performance

Historical Comparison
PRE
ADAG

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: